NextCure, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 21, 2024. NextCure is a clinical-stage biopharmaceutical company with no products approved for sale and no product-sales revenue.
Business context and pipeline
The company focuses on cancer therapies, particularly NC410, a LAIR-2 fusion protein being studied with pembrolizumab, and LNCB74, a B7-H4 antibody-drug conjugate being developed with LegoChem Biosciences. Other programs include clinical candidates NC525 and NC318 and preclinical candidates NC605 and NC181.
Key financial metrics
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Product-sales revenue | None | None |
| Research and development expense | $47.9 million | $54.2 million |
| General and administrative expense | $19.7 million | $21.7 million |
| Operating loss | $67.6 million | $75.9 million |
| Net loss | $62.7 million; $2.25 per share | $74.7 million; $2.69 per share |
| Other income, net | $4.9 million | $1.2 million |
| Operating cash used | $53.0 million | $53.9 million |
| Cash, cash equivalents and marketable securities | $108.3 million | $159.9 million |
| Total assets / total liabilities | $128.0 million / $13.6 million | $184.2 million / $16.6 million |
Gross margin is not meaningful because NextCure had no product-sales revenue. The balance sheet reports no borrowings; long-term lease liabilities were $5.9 million, with total operating lease liabilities of $6.6 million. Cash used in investing activities was $39.3 million, primarily reflecting net proceeds from marketable securities, rather than operating cash generation. The company reported an accumulated deficit of $324.5 million.
Material changes and notable items
- Net loss narrowed by $12.0 million year over year, as operating expenses declined and interest income increased. R&D expense fell 12%, principally following the discontinuation of NC762 and lower spending on other programs; NC410 spending increased.
- Cash, cash equivalents and marketable securities declined by $51.6 million year over year. The company reported $13.1 million of cash and cash equivalents and $95.2 million of marketable securities at year-end.
- In December 2023, NextCure announced it would discontinue NC762’s monotherapy Phase 2 trial. In March 2024, it announced a broader prioritization and restructuring: pause internal manufacturing, reduce its workforce from 82 employees at year-end to approximately 51, and seek partners for NC525, NC318, NC605 and NC181.
- The March 2024 restructuring is a subsequent event, not a FY2023 operating change. The company estimated approximately $0.8 million in one-time restructuring charges, mainly payable in Q2 2024.
Outlook, management commentary and risks
- Management expects several NC410 clinical catalysts in 2024: colorectal cancer data in Q2 and ovarian cancer data in the second half. It reported preliminary results as of February 23, 2024: NC410 plus pembrolizumab had a 10.5% response rate among 19 evaluable colorectal cancer patients and a 42.8% response rate among seven evaluable ovarian cancer patients. These are small, early-stage datasets; ovarian responses were not all confirmed.
- NextCure plans to file an IND for LNCB74 by year-end 2024. This remains a development target, not an assured outcome.
- Management projects the restructuring will extend cash runway into the second half of 2026. Elsewhere, the financial-statement liquidity note says existing cash is expected to fund operations to mid-2026 and cautions that funding beyond two years from issuance is not assured. Runway depends on assumptions and development spending.
- The company has a $75 million at-the-market stock offering facility, but had sold no shares under it by December 31, 2023. Additional financing may be required and could dilute shareholders or require rights to be licensed or partnered.
- Principal risks include clinical and regulatory failure, early results not holding up in larger trials, patient enrollment, manufacturing and third-party supply dependencies, competition, limited patent protection, reliance on collaborators, and the need for additional capital. The internal manufacturing pause makes the transition to external manufacturing and supply worth monitoring.
- The company disclosed a third-party lawsuit alleging misuse of confidential information and breach of duties involving its CEO and discovery efforts; the filing’s risk discussion describes the allegations, while the legal-proceedings note says management is not aware of pending matters likely to materially affect the company. Verify the case’s current status and any resolution.
Most important facts for investors to verify
- Whether NC410’s preliminary response and disease-control findings are confirmed in expanded patient groups, and whether subsequent data establish meaningful clinical benefit.
- Whether LNCB74 meets its IND timeline, and whether manufacturing, safety and collaboration milestones remain on track.
- Actual cash burn and runway after the restructuring, including reconciliation of the filing’s mid-2026 and second-half-2026 estimates and any future financing or ATM sales.
- Execution and costs of the workforce reduction and manufacturing pause, and the availability of dependable third-party clinical supply.
- The status and potential consequences of the disclosed litigation, and any material changes in partnering plans for NC525, NC318 and the preclinical programs.
The independent auditor issued an unqualified opinion on the FY2023 financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness because the company qualified for the emerging-growth-company exemption.